NDC 42291-017 Acyclovir


NDC Product Code 42291-017

NDC Code: 42291-017

Proprietary Name: Acyclovir Additional informationCallout TooltipWhat is the Proprietary Name?
The proprietary name also known as the trade name is the name of the product chosen by the medication labeler for marketing purposes.

Non-Proprietary Name: Acyclovir Additional informationCallout TooltipWhat is the Non-Proprietary Name?
The non-proprietary name is sometimes called the generic name. The generic name usually includes the active ingredient(s) of the product.

Product Characteristics
Shape: CAPSULE (C48336)
18 MM
Score: 1

Code Structure
  • 42291 - Avkare, Inc.
    • 42291-017 - Acyclovir

NDC 42291-017-01

Package Description: 100 CAPSULE in 1 BOTTLE

NDC 42291-017-50

Package Description: 500 CAPSULE in 1 BOTTLE

NDC Product Information

Acyclovir with NDC 42291-017 is a a human prescription drug product labeled by Avkare, Inc.. The generic name of Acyclovir is acyclovir. The product's dosage form is capsule and is administered via oral form.

Labeler Name: Avkare, Inc.

Dosage Form: Capsule - A solid oral dosage form consisting of a shell and a filling. The shell is composed of a single sealed enclosure, or two halves that fit together and which are sometimes sealed with a band. Capsule shells may be made from gelatin, starch, or cellulose, or other suitable materials, may be soft or hard, and are filled with solid or liquid ingredients that can be poured or squeezed.

Product Type: Human Prescription Drug Additional informationCallout TooltipWhat kind of product is this?
Indicates the type of product, such as Human Prescription Drug or Human Over the Counter Drug. This data element matches the “Document Type” field of the Structured Product Listing.

Acyclovir Active Ingredient(s)

Additional informationCallout TooltipWhat is the Active Ingredient(s) List?
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.

  • ACYCLOVIR 200 mg/1

Inactive Ingredient(s)

Additional informationCallout TooltipAbout the Inactive Ingredient(s)
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product.

  • GELATIN (UNII: 2G86QN327L)
  • FD&C BLUE NO. 1 (UNII: H3R47K3TBD)
  • AMMONIA (UNII: 5138Q19F1X)
  • ALCOHOL (UNII: 3K9958V90M)
  • SHELLAC (UNII: 46N107B71O)

Administration Route(s)

Additional informationCallout TooltipWhat are the Administration Route(s)?
The translation of the route code submitted by the firm, indicating route of administration.

  • Oral - Administration to or by way of the mouth.

Pharmacological Class(es)

Additional informationCallout TooltipWhat is a Pharmacological Class?
These are the reported pharmacological class categories corresponding to the SubstanceNames listed above.

  • DNA Polymerase Inhibitors - [MoA] (Mechanism of Action)
  • Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor - [EPC] (Established Pharmacologic Class)
  • Herpes Zoster Virus Nucleoside Analog DNA Polymerase Inhibitor - [EPC] (Established Pharmacologic Class)
  • Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor - [EPC] (Established Pharmacologic Class)
  • Nucleoside Analog - [EXT]

Product Labeler Information

Additional informationCallout TooltipWhat is the Labeler Name?
Name of Company corresponding to the labeler code segment of the Product NDC.

Labeler Name: Avkare, Inc.
Labeler Code: 42291
FDA Application Number: ANDA075677 Additional informationCallout TooltipWhat is the FDA Application Number?
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.

Marketing Category: ANDA - A product marketed under an approved Abbreviated New Drug Application. Additional informationCallout TooltipWhat is the Marketing Category?
Product types are broken down into several potential Marketing Categories, such as NDA/ANDA/BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Start Marketing Date: 01-15-2019 Additional informationCallout TooltipWhat is the Start Marketing Date?
This is the date that the labeler indicates was the start of its marketing of the drug product.

Listing Expiration Date: 12-31-2020 Additional informationCallout TooltipWhat is the Listing Expiration Date?
This is the date when the listing record will expire if not updated or certified by the product labeler.

Exclude Flag: N Additional informationCallout TooltipWhat is the NDC Exclude Flag?
This field indicates whether the product has been removed/excluded from the NDC Directory for failure to respond to FDA’s requests for correction to deficient or non-compliant submissions. Values = ‘Y’ or ‘N’.

* Please review the disclaimer below.

Information for Patients


Acyclovir is pronounced as (ay sye' kloe veer)

Why is acyclovir medication prescribed?
Acyclovir is used to decrease pain and speed the healing of sores or blisters in people who have varicella (chickenpox), herpes zoster (shingles; a rash that can occur in...
[Read More]

* Please review the disclaimer below.

Acyclovir Product Label Images

Acyclovir Product Labeling Information

The product labeling information includes all published material associated to a drug. Product labeling documents include information like generic names, active ingredients, ingredient strength dosage, routes of administration, appearance, usage, warnings, inactive ingredients, etc.

Product Labeling Index


Acyclovir is a synthetic nucleoside analogue active against herpes viruses. Acyclovir capsule is a formulation for oral administration. Each capsule of acyclovir contains 200 mg of acyclovir and the inactive ingredients colloidal silicon dioxide, croscarmellose sodium, magnesium stearate and microcrystalline cellulose. The capsule shell consists of FD&C blue #1, gelatin and titanium dioxide. The capsule black imprinting ink contains the following inactive ingredients: ammonium hydroxide, black iron oxide, n-butyl, ethyl alcohol, isopropyl alcohol, potassium hydroxide, propylene glycol and shellac.

Acyclovir is a white, crystalline powder with the molecular formula C




3 and a molecular weight of 225.2. The maximum solubility in water at 37°C is 2.5 mg/mL. The pka’s of acyclovir are 2.27 and 9.25.

The chemical name of acyclovir is 2-amino-1,9-dihydro-9-[(2-hydroxyethoxy)methyl]-6

H-purin-6-one; it has the following structural formula:

Mechanism Of Antiviral Action

Acyclovir is a synthetic purine nucleoside analogue with
in vitro and in vivo inhibitory activity against herpes simplex
virus types 1 (HSV-1), 2 (HSV-2), and varicella-zoster virus (VZV). The
inhibitory activity of acyclovir is highly selective due to its affinity for
the enzyme thymidine kinase (TK) encoded by HSV and VZV. This viral enzyme
converts acyclovir into acyclovir monophosphate, a nucleotide analogue. The
monophosphate is further converted into diphosphate by cellular guanylate
kinase and into triphosphate by a number of cellular enzymes. In vitro, acyclovir
triphosphate stops replication of herpes viral DNA. This is accomplished in
3 ways: 1) competitive inhibition of viral DNA polymerase, 2) incorporation
into and termination of the growing viral DNA chain, and 3) inactivation of
the viral DNA polymerase. The greater antiviral activity of acyclovir against
HSV compared to VZV is due to its more efficient phosphorylation by the viral

Antiviral Activities

The quantitative relationship between the in vitro susceptibility of herpes viruses to antivirals and the clinical response to therapy has not been established in humans, and virus sensitivity testing has not been standardized. Sensitivity testing results, expressed as the concentration of drug required to inhibit by 50% the growth of virus in cell culture (IC

50), vary greatly depending upon a number of factors. Using plaque-reduction assays, the IC

50 against herpes simplex virus isolates ranges from 0.02 to 13.5 mcg/mL for HSV-1 and from 0.01 to 9.9 mcg/mL for HSV-2. The IC

50 for acyclovir against most laboratory strains and clinical isolates of VZV ranges from 0.12 to 10.8 mcg/mL. Acyclovir also demonstrates activity against the Oka vaccine strain of VZV with a mean IC

50 of
1.35 mcg/mL.

Drug Resistance

Resistance of HSV and VZV to acyclovir can result from qualitative
and quantitative changes in the viral TK and/or DNA polymerase. Clinical isolates
of HSV and VZV with reduced susceptibility to acyclovir have been recovered
from immunocompromised patients, especially with advanced HIV infection. While
most of the acyclovir-resistant mutants isolated thus far from immunocompromised
patients have been found to be TK-deficient mutants, other mutants involving
the viral TK gene (TK partial and TK altered) and DNA polymerase have been
isolated. TK-negative mutants may cause severe disease in infants and immunocompromised
adults. The possibility of viral resistance to acyclovir should be considered
in patients who show poor clinical response during therapy.


The pharmacokinetics of acyclovir after oral administration have been evaluated in healthy volunteers and in immunocompromised patients with herpes simplex or varicella-zoster virus infection. Acyclovir pharmacokinetic parameters are summarized in Table 1.Table 1. Acyclovir Pharmacokinetic Characteristics (Range) ParameterRangePlasma protein binding9% to 33%Plasma elimination half-life2.5 to 3.3 hAverage oral bioavailability10% to 20%**Bioavailability decreases with increasing
dose.In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown in Table 2. The decrease in bioavailability is a function of the dose and not the dosage form.Table 2. Acyclovir Peak and Trough Concentrations at Steady StateParameter200 mg400 mg800 mg0.83 mcg/mL1.21 mcg/mL1.61 mcg/mL0.46 mcg/mL0.63 mcg/mL0.83 mcg/mLThere was no effect of food on the absorption of acyclovir (n = 6); therefore, acyclovir capsules may be administered with or without food.The only known urinary metabolite is 9-[(carboxymethoxy)methyl]guanine.

Adults With Impaired Renal Function

The half-life and total body clearance of acyclovir are dependent on renal function. A dosage adjustment is recommended for patients with reduced renal function (see



Acyclovir plasma concentrations are higher in geriatric patients compared to younger adults, in part due to age-related changes in renal function. Dosage reduction may be required in geriatric patients with underlying renal impairment (see

PRECAUTIONS: Geriatric Use).


In general, the
pharmacokinetics of acyclovir in pediatric patients is similar to that of
adults. Mean half-life after oral doses of 300 mg/m

2 and 600 mg/m

2 in
pediatric patients aged 7 months to 7 years was 2.6 hours (range
1.59 to 3.74 hours).

Drug Interactions

Coadministration of probenecid with intravenous acyclovir
has been shown to increase the mean acyclovir half-life and the area under
the concentration-time curve. Urinary excretion and renal clearance were correspondingly



Initial Genital Herpes

Double-blind, placebo-controlled studies have demonstrated that orally administered acyclovir significantly reduced the duration of acute infection and duration of lesion healing. The duration of pain and new lesion formation was decreased in some patient groups.

Recurrent Genital Herpes

Double-blind, placebo-controlled studies in patients with frequent recurrences (6 or more episodes per year) have shown that orally administered acyclovir given daily for 4 months to 10 years prevented or reduced the frequency and/or severity of recurrences in greater than 95% of patients.

In a study of patients who received acyclovir

400 mg twice daily for 3 years, 45%, 52%, and 63% of patients remained free of recurrences in the first, second, and third years, respectively. Serial analyses of the 3-month recurrence rates for the patients showed that 71% to 87% were recurrence free in each quarter.

Herpes Zoster Infections

In a double-blind, placebo-controlled study of immunocompetent patients with localized cutaneous zoster infection, acyclovir (800 mg 5 times daily for 10 days) shortened the times to lesion scabbing, healing, and complete cessation of pain, and reduced the duration of viral shedding and the duration of new lesion formation.

In a similar double-blind, placebo-controlled study, acyclovir (800 mg 5 times daily for 7 days) shortened the times to complete lesion scabbing, healing, and cessation of pain; reduced the duration of new lesion formation; and reduced the prevalence of localized zoster-associated neurologic symptoms (paresthesia, dysesthesia, or hyperesthesia).Treatment was begun within 72 hours of rash onset and was most effective if started within the first 48 hours.Adults greater than 50 years of age showed greater benefit.

Acyclovir capsule is indicated for the acute treatment of herpes zoster (shingles).


Three randomized, double-blind, placebo-controlled trials were conducted in 993 pediatric patients aged 2 to 18 years with chickenpox. All patients were treated within 24 hours after the onset of rash. In 2 trials, acyclovir was administered at 20 mg/kg 4 times daily (up to 3,200 mg per day) for 5 days. In the third trial, doses of 10, 15, or 20 mg/kg were administered 4 times daily for 5 to 7 days. Treatment with acyclovir shortened the time to 50% healing; reduced the maximum number of lesions; reduced the median number of vesicles; decreased the median number of residual lesions on day 28; and decreased the proportion of patients with fever, anorexia, and lethargy by day 2. Treatment with acyclovir did not affect varicella-zoster virus-specific humoral or cellular immune responses at 1 month or 1 year following treatment.

Acyclovir capsule is indicated for the treatment of chickenpox (varicella).

Chickenpox in otherwise healthy children is usually a self-limited
disease of mild to moderate severity. Adolescents and adults tend to have
more severe disease. Treatment was initiated within 24 hours of the typical
chickenpox rash in the controlled studies, and there is no information regarding
the effects of treatment begun later in the disease course.

The most frequent adverse event reported during 3 clinical
trials of treatment of chickenpox with oral acyclovir at doses of 10 to 20 mg/kg
4 times daily for 5 to 7 days or 800 mg 4 times daily
for 5 days in 495 patients was diarrhea (3.2%). The 498 patients
receiving placebo reported diarrhea (2.2%).

Genital Herpes

Acyclovir capsule is indicated for the treatment of initial episodes and the management of recurrent episodes of genital herpes.


Acyclovir is contraindicated for patients who develop hypersensitivity to acyclovir or valacyclovir.


Acyclovir capsule is

intended for oral ingestion only. Renal failure, in some cases resulting in death, has been observed with acyclovir therapy (see

ADVERSE REACTIONS: Observed During Clinical Practice and

OVERDOSAGE). Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS), which has resulted in death, has occurred in immunocompromised patients receiving acyclovir therapy.


Dosage adjustment is recommended when administering acyclovir to patients with renal impairment (see

DOSAGE AND ADMINISTRATION). Caution should also be exercised when administering acyclovir to patients receiving potentially nephrotoxic agents since this may increase the risk of renal dysfunction and/or the risk of reversible central nervous system symptoms such as those that have been reported in patients treated with intravenous acyclovir. Adequate hydration should be maintained.

Information For Patients

Patients are instructed to consult with their physician
if they experience severe or troublesome adverse reactions, they become pregnant
or intend to become pregnant, they intend to breastfeed while taking orally
administered acyclovir, or they have any other questions. Patients
should be advised to maintain adequate hydration.

Herpes Zoster

There are no data on treatment initiated more than 72 hours
after onset of the zoster rash. Patients should be advised to initiate treatment
as soon as possible after a diagnosis of herpes zoster.

The most frequent adverse event reported during 3 clinical
trials of treatment of herpes zoster (shingles) with 800 mg of oral acyclovir
5 times daily for 7 to 10 days in 323 patients was malaise
(11.5%). The 323 placebo recipients reported malaise (11.1%).

Genital Herpes Infections

Patients should be informed that acyclovir is not a cure for
genital herpes. There are no data evaluating whether acyclovir will prevent
transmission of infection to others. Because genital herpes is a sexually
transmitted disease, patients should avoid contact with lesions or intercourse
when lesions and/or symptoms are present to avoid infecting partners. Genital
herpes can also be transmitted in the absence of symptoms through asymptomatic
viral shedding. If medical management of a genital herpes recurrence is indicated,
patients should be advised to initiate therapy at the first sign or symptom
of an episode.

Carcinogenesis, Mutagenesis, Impairment Of Fertility

The data presented below include references to peak steady-state plasma acyclovir concentrations observed in humans treated with 800 mg given orally 5 times a day (dosing appropriate for treatment of herpes zoster) or 200 mg given orally 5 times a day (dosing appropriate for treatment of genital herpes). Plasma drug concentrations in animal studies are expressed as multiples of human exposure to acyclovir at the higher and lower dosing schedules (see


was tested in lifetime bioassays in rats and mice at single daily doses of
up to 450 mg/kg administered by gavage. There was no statistically significant
difference in the incidence of tumors between treated and control animals,
nor did acyclovir shorten the latency of tumors. Maximum plasma concentrations
were 3 to 6 times human levels in the mouse bioassay and 1 to 2 times
human levels in the rat bioassay. Acyclovir was tested
in 16 in vitro and in vivo genetic toxicity assays. Acyclovir was positive
in 5 of the assays. Acyclovir did not impair fertility
or reproduction in mice (450 mg/kg/day, p.o.) or in rats (25 mg/kg/day,
s.c.). In the mouse study, plasma levels were 9 to 18 times human levels,
while in the rat study, they were 8 to 15 times human levels. At higher
doses (50 mg/kg/day, s.c.) in rats and rabbits (11 to 22 and 16 to 31 times
human levels, respectively) implantation efficacy, but not litter size, was
decreased. In a rat peri- and post-natal study at 50 mg/kg/day, s.c.,
there was a statistically significant decrease in group mean numbers of corpora
lutea, total implantation sites, and live fetuses. No
testicular abnormalities were seen in dogs given 50 mg/kg/day, IV for
1 month (21 to 41 times human levels) or in dogs given 60 mg/kg/day
orally for 1 year (6 to 12 times human levels). Testicular atrophy
and aspermatogenesis were observed in rats and dogs at higher dose levels.

Teratogenic Effects

Pregnancy Category
B. Acyclovir administered during organogenesis was not teratogenic in the
mouse (450 mg/kg/day, p.o.), rabbit (50 mg/kg/day, s.c. and IV),
or rat (50 mg/kg/day, s.c.). These exposures resulted in plasma levels
9 and 18, 16 and 106, and 11 and 22 times, respectively, human levels.

There are no adequate and
well-controlled studies in pregnant women. A prospective epidemiologic registry
of acyclovir use during pregnancy was established in 1984 and completed in
April 1999. There were 749 pregnancies followed in women exposed to systemic
acyclovir during the first trimester of pregnancy resulting in 756 outcomes.
The occurrence rate of birth defects approximates that found in the general
population. However, the small size of the registry is insufficient to evaluate
the risk for less common defects or to permit reliable or definitive conclusions
regarding the safety of acyclovir in pregnant women and their developing fetuses.
Acyclovir should be used during pregnancy only if the potential benefit justifies
the potential risk to the fetus.

Nursing Mothers

Acyclovir concentrations have been documented in breast milk in 2 women following oral administration of acyclovir and ranged from 0.6 to 4.1 times corresponding plasma levels. These concentrations would potentially expose the nursing infant to a dose of acyclovir up to 0.3 mg/kg/day. Acyclovir should be administered to a nursing mother with caution and only when indicated.

Pediatric Use

Safety and effectiveness of oral formulations of acyclovir
in pediatric patients younger than 2 years of age have not been established.

Geriatric Use

Of 376 subjects who received acyclovir in a clinical study of herpes zoster treatment in immunocompetent subjects ≥50 years of age, 244 were 65 and over while 111 were 75 and over. No overall differences in effectiveness for time to cessation of new lesion formation or time to healing were reported between geriatric subjects and younger adult subjects. The duration of pain after healing was longer in patients 65 and over. Nausea, vomiting, and dizziness were reported more frequently in elderly subjects. Elderly patients are more likely to have reduced renal function and require dose reduction. Elderly patients are also more likely to have renal or CNS adverse events. With respect to CNS adverse events observed during clinical practice, somnolence, hallucinations, confusion, and coma were reported more frequently in elderly patients (see


ADVERSE REACTIONS: Observed During Clinical Practice, and


Short-Term Administration

The most frequent
adverse events reported during clinical trials of treatment of genital herpes
with acyclovir 200 mg administered orally 5 times daily every 4 hours
for 10 days were nausea and/or vomiting in 8 of 298 patient treatments
(2.7%). Nausea and/or vomiting occurred in 2 of 287 (0.7%) patients who received

Long-Term Administration

The most frequent
adverse events reported in a clinical trial for the prevention of recurrences
with continuous administration of 400 mg (two 200-mg capsules) 2 times
daily for 1 year in 586 patients treated with acyclovir were nausea
(4.8%) and diarrhea (2.4%). The 589 control patients receiving intermittent
treatment of recurrences with acyclovir for 1 year reported diarrhea (2.7%),
nausea (2.4%), and headache (2.2%).

Observed During Clinical Practice

In addition to adverse events reported from clinical trials,
the following events have been identified during post-approval use of acyclovir.
Because they are reported voluntarily from a population of unknown size, estimates
of frequency cannot be made. These events have been chosen for inclusion due
to either their seriousness, frequency of reporting, potential causal connection
to acyclovir, or a combination of these factors.


Anaphylaxis, angioedema,
fever, headache, pain, peripheral edema.


Aggressive behavior,
agitation, ataxia, coma,

confusion, decreased consciousness, delirium, dizziness, dysarthria, encephalopathy, hallucinations, paresthesia, psychosis, seizure, somnolence, tremors. These symptoms may be marked, particularly in older adults or in patients with renal impairment (see



Diarrhea, gastrointestinal distress, nausea.

Hematologic And Lymphatic

Anemia, leukocytoclastic
vasculitis, leukopenia, lymphadenopathy, thrombocytopenia.

Hepatobiliary Tract And Pancreas

Elevated liver function tests, hepatitis, hyperbilirubinemia,




Alopecia, erythema multiforme,
photosensitive rash, pruritus, rash, Stevens-Johnson syndrome, toxic epidermal
necrolysis, urticaria.

Special Senses

Visual abnormalities.


Renal failure, elevated blood urea nitrogen, elevated creatinine, hematuria (see



Overdoses involving ingestion of up to 100 capsules (20 g) have been reported. Adverse events that have been reported in association with overdosage include agitation, coma, seizures, and lethargy. Precipitation of acyclovir in renal tubules may occur when the solubility (2.5 mg/mL) is exceeded in the intratubular fluid. Overdosage has been reported following bolus injections or inappropriately high doses and in patients whose fluid and electrolyte balance were not properly monitored. This has resulted in elevated BUN and serum creatinine and subsequent renal failure. In the event of acute renal failure and anuria, the patient may benefit from hemodialysis until renal function is restored (see


Acute Treatment Of Herpes Zoster

800 mg every 4 hours orally, 5 times daily
for 7 to 10 days.

Treatment Of Initial Genital Herpes

200 mg every
4 hours, 5 times daily for 10 days.

Chronic Suppressive Therapy For Recurrent Disease

400 mg 2 times
daily for up to 12 months, followed by re-evaluation. Alternative regimens
have included doses ranging from 200 mg 3 times daily to 200 mg
5 times daily.

The frequency and severity of episodes
of untreated genital herpes may change over time. After 1 year of therapy,
the frequency and severity of the patient’s genital herpes infection
should be re-evaluated to assess the need for continuation of therapy with

Intermittent Therapy

200 mg every
4 hours, 5 times daily for 5 days. Therapy should be initiated
at the earliest sign or symptom (prodrome) of recurrence.

Children (2 Years Of Age And Older)

20 mg/kg

per dose orally
4 times daily (80 mg/kg/day) for 5 days. Children over 40 kg
should receive the adult dose for chickenpox.

Adults And Children Over 40 Kg

800 mg 4 times
daily for 5 days.

Intravenous acyclovir is indicated
for the treatment of varicella-zoster infections in immunocompromised patients. When
therapy is indicated, it should be initiated at the earliest sign or symptom
of chickenpox. There is no information about the efficacy of therapy initiated
more than 24 hours after onset of signs and symptoms.

Patients With Acute Or Chronic Renal Impairment

In patients with renal impairment, the dose of acyclovir should be modified as shown in Table 3:Table 3. Dosage Modification for Renal ImpairmentCreatinineAdjusted Dosage RegimenNormal DosageRegimenClearance(mL/min/1.73 m


Dose(mg)Dosing Interval200 mg every 4 hours>10200every 4 hours, 5x daily0-10200every 12 hours400 mg every 12 hours>100-10400200every 12 hoursevery
12 hours800 mg every 4 hours>25800every 4 hours, 5x daily10-25800every 8 hours0-10800every 12 hours


For patients who require hemodialysis, the mean plasma half-life
of acyclovir during hemodialysis is approximately 5 hours. This results
in a 60% decrease in plasma concentrations following a 6-hour dialysis period.
Therefore, the patient’s dosing schedule should be adjusted so that
an additional dose is administered after each dialysis.

Peritoneal Dialysis

No supplemental dose appears to be necessary after adjustment
of the dosing interval.

How Supplied

Acyclovir Capsules USP 200 mg are available for oral administration as hard gelatin capsules with a white opaque body and an aqua blue opaque cap. “APO 042” is imprinted on each capsule in black ink. They are supplied as follows:Bottles of 100 (42291-017-01)Bottles of 500 (42291-017-50)Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature] and protect from moisture.Manufactured for:

AvKARE, Inc.

Pulaski, TN 38478
Mfg. Rev. 12/05

AV 01/19 (P)

* Please review the disclaimer below.

Previous Code
Next Code